» Articles » PMID: 35525861

Persistence of C-reactive Protein Increased Levels and High Disease Activity Are Predictors of Cardiovascular Disease in Patients with Axial Spondyloarthritis

Abstract

An accurate prediction of cardiovascular (CV) risk in patients with Axial Spondyloarthritis (axSpA) is a strong unmet need, as CV risk algorithms poorly perform in these subjects. The aim of this study was to establish whether the persistence of high C-reactive protein (CRP) and high disease activity may be considered predictive factors of CVD in axSpA. 295 patients without personal history of CVD, were consecutively enrolled in this study. To evaluate the relationship between CV events occurrence (fatal and non-fatal) and the persistence of increased CRP levels, ASDAS (Ankylosing Spondylitis Disease Activity Score) > 2.1, and BASDAI (Bath Ankylosing Spondylitis Disease Activity) > 4 during the follow-up, univariable and multivariable Cox Proportional Hazard Models have been performed. During follow-up (we analyzed 10-years retrospective data), 23 patients had a CV event. Multivariable Cox Proportional Hazard Models showed a strong association between CV event and the persistency of increased CRP levels (namely, percentage of visits in which CRP levels were increased) (HR = 1.03; 95%CI 1.015-1.045; p < 0.001), of ASDAS > 2.1 (HR = 1.014, 95%CI 1.000-1.028, p = 0.047), and of BASDAI > 4 (HR 1.019, 95%CI 1.006-1.033, p = 0.006) during follow-up, after adjustment for age, sex, and diabetes. This study suggests that persistence of increased CRP levels and high disease activity may be considered biomarkers to identify those axSpA patients at higher risk of CVD. Innovative axSpA-specific CV risk score, including these variables, have to be developed.

Citing Articles

Sex-specific impact of inflammation on traditional cardiovascular risk factors and atherosclerosis in axial spondyloarthritis. A multicentre study of 913 patients.

Ferraz-Amaro I, Genre F, Blanco R, Calvo-Rio V, Corrales-Selaya C, Portilla V RMD Open. 2024; 10(2).

PMID: 38942590 PMC: 11227836. DOI: 10.1136/rmdopen-2024-004187.


Use of risk chart algorithms for the identification of psoriatic arthritis patients at high risk for cardiovascular disease: findings derived from the project CARMA cohort after a 7.5-year follow-up period.

Polo Y La Borda J, Castaneda S, Heras-Recuero E, Sanchez-Alonso F, Plaza Z, Garcia Gomez C RMD Open. 2024; 10(2).

PMID: 38631846 PMC: 11029293. DOI: 10.1136/rmdopen-2024-004207.


Increased Prevalence of Headaches and Migraine in Patients with Psoriatic Arthritis and Axial Spondyloarthritis: Insights from an Italian Cohort Study.

Marino A, Currado D, Altamura C, Vomero M, Berardicurti O, Corberi E Biomedicines. 2024; 12(2).

PMID: 38397972 PMC: 10886921. DOI: 10.3390/biomedicines12020371.


Cardiovascular risk in axial spondyloarthritis-a systematic review.

Hintenberger R, Affenzeller B, Vladychuk V, Pieringer H Clin Rheumatol. 2023; 42(10):2621-2633.

PMID: 37418034 PMC: 10497445. DOI: 10.1007/s10067-023-06655-z.


Cardiovascular Disease and Cardiac Imaging in Inflammatory Arthritis.

Madenidou A, Mavrogeni S, Nikiphorou E Life (Basel). 2023; 13(4).

PMID: 37109438 PMC: 10143346. DOI: 10.3390/life13040909.


References
1.
Hippisley-Cox J, Coupland C, Brindle P . Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017; 357:j2099. PMC: 5441081. DOI: 10.1136/bmj.j2099. View

2.
Ruscitti P, Cipriani P, Masedu F, Romano S, Berardicurti O, Liakouli V . Increased Cardiovascular Events and Subclinical Atherosclerosis in Rheumatoid Arthritis Patients: 1 Year Prospective Single Centre Study. PLoS One. 2017; 12(1):e0170108. PMC: 5245879. DOI: 10.1371/journal.pone.0170108. View

3.
Navarini L, Currado D, Costa L, Tasso M, Chimenti M, Caso F . Experimental and Investigational Pharmacotherapy for Psoriatic Arthritis: Drugs of the Future. J Exp Pharmacol. 2020; 12:487-502. PMC: 7679354. DOI: 10.2147/JEP.S265633. View

4.
England B, Thiele G, Anderson D, Mikuls T . Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications. BMJ. 2018; 361:k1036. PMC: 6889899. DOI: 10.1136/bmj.k1036. View

5.
Pletcher M, Moran A . Cardiovascular Risk Assessment. Med Clin North Am. 2017; 101(4):673-688. DOI: 10.1016/j.mcna.2017.03.002. View